We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+22.77%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$12.2B
AUM Growth
+$2.02B
Cap. Flow
+$1.08B
Cap. Flow %
8.87%
Top 10 Hldgs %
86.71%
Holding
137
New
4
Increased
21
Reduced
9
Closed
18

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$1.35B
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$11.4M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$9.33M
4
ASND icon
Ascendis Pharma A/S
ASND
+$8.29M
5
NGNE icon
Neurogene
NGNE
+$6.99M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$106M
2
DSCI
Derma Sciences, Inc. Common Stock (DE)
DSCI
+$19.5M
3
ARRY
Array Biopharma Inc
ARRY
+$10.6M
4
EXEL icon
Exelixis
EXEL
+$8.13M
5
ARCT icon
Arcturus Therapeutics
ARCT
+$4.91M

Sector Composition

Rank Sector Weight
1 Healthcare 92.12%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
1
Incyte
INCY
$25.4B
$4.56B 37.31%
34,110,011
+10,610,924
+45% +$1.35B
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$2.87B 23.51%
45,715,556
+3,700
+0% +$231K
ACAD icon
3
Acadia Pharmaceuticals
ACAD
$4.47B
$888M 7.26%
25,819,768
– –
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
$793M 6.49%
6,544,130
+835
+0% +$108K
GHDX
5
DELISTED
Genomic Health, Inc.
GHDX
$434M 3.55%
13,770,982
+680
+0% +$20.1K
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$11.8B
$422M 3.45%
4,806,483
– –
DBVT
7
DBV Technologies
DBVT
$812M
$194M 1.59%
550,956
– –
NGNE icon
8
Neurogene
NGNE
$663M
$182M 1.49%
546,708
+19,903
+4% +$6.99M
ONC
9
BeOne Medicines Ltd
ONC
$33.9B
$134M 1.1%
3,673,175
– –
AKAO
10
DELISTED
Achaogen Inc
AKAO
$116M 0.95%
4,582,382
– –
BCRX icon
11
BioCryst Pharmaceuticals
BCRX
$2.42B
$98.4M 0.81%
11,716,784
+752,840
+7% +$5.24M
AAAP
12
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$88.6M 0.72%
2,221,706
+54,569
+3% +$1.88M
NVTA
13
DELISTED
Invitae Corporation
NVTA
$80.6M 0.66%
7,288,300
– –
AMRN
14
Amarin Corp
AMRN
$297M
$72.5M 0.59%
1,132,823
+24,348
+2% +$1.55M
ONCE
15
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$70.3M 0.58%
1,318,341
– –
ACOR
16
DELISTED
Acorda Therapeutics
ACOR
$69.3M 0.57%
27,515
– –
BLCM
17
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$62.1M 0.51%
503,231
+16,666
+3% +$2.18M
CERS icon
18
Cerus
CERS
$571M
$58.1M 0.48%
13,053,275
– –
EXEL icon
19
Exelixis
EXEL
$13.9B
$56.4M 0.46%
2,603,569
-400,000
-13% -$8.13M
HRTX icon
20
Heron Therapeutics
HRTX
$93.1M
$41.8M 0.34%
2,783,569
+400,000
+17% +$5.54M
NBIX icon
21
Neurocrine Biosciences
NBIX
$18.2B
$38.8M 0.32%
895,422
– –
AVXS
22
DELISTED
AveXis, Inc. Common Stock
AVXS
$38M 0.31%
500,000
+184,700
+59% +$11.4M
ASND icon
23
Ascendis Pharma A/S
ASND
$16.6B
$37.8M 0.31%
1,351,463
+328,197
+32% +$8.29M
ARAV
24
DELISTED
Aravive, Inc. Common Stock
ARAV
$35.5M 0.29%
276,766
-43,375
-14% -$4.57M
BLUE
25
DELISTED
bluebird bio
BLUE
$31.9M 0.26%
27,131
– –
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2017 Portfolio in Review

As of Q1 2017, Baker Bros. Advisors held 137 positions worth $12.2B, up 20% from $10.2B the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Baker Bros. Advisors deployed $1.08B of net new capital in Q1 2017, opening 4 new positions and adding to 21 existing holdings. Its largest new stake was AnaptysBio: 150,000 shares worth $4.16M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 82% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $10.6M trimmed.

  • Baker Bros. Advisors's largest Q1 2017 buy was AnaptysBio: 150,000 shares worth $4.16M.
  • Baker Bros. Advisors added most to Incyte in Q1 2017, an estimated $1.35B increase.
  • Baker Bros. Advisors's biggest Q1 2017 reduction was Array Biopharma Inc, cutting an estimated $10.6M.
  • Baker Bros. Advisors fully exited AbbVie in Q1 2017, selling an estimated $106M.
  • Baker Bros. Advisors's ten largest holdings make up 87% of its $12.2B portfolio in Q1 2017.
  • Baker Bros. Advisors opened 4 new positions and closed 18 in Q1 2017.
  • Baker Bros. Advisors's portfolio value rose 20% quarter-over-quarter to $12.2B.

Based on Baker Bros. Advisors's 13F filing for Q1 2017, filed 15 May 2017.